PolySon™ T Options Available:1 vial (5×100 μL injections) activation with the UltraMix device

activation with the UltraMix device ensures prescribed size distribution of the agents and consistent performance

HAR-PHM-123-10 | 10 mL syringe

Mass: 600g

Study inflammatory processes such as in rheumatic diseases

The agent accumulates in atherosclerotic plaques and enables T1-weighted visualization of plaque burden

PolySon™ T Options Available:1 vial (5×100 μL injections) activation with the UltraMix deviceViscovers innovative ultrasound agent PolySon T consists of microbubbles, which are optimized for imaging of tumors. The agents exceptionally high contrast enhancement coupled with its long blood half life enables improved visualization of vascularized tumors in animal tumor models. The innovative ultrasound agent, PolySon T: Is highly echogenic delivering optimal contrast at all typically used frequencies Has a long circulation time enabling a wide